BioMimetic Therapeutics (BMTI) Posts Q1 Loss of 22c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/7/2026
- S&P 500, Nasdaq reach record closing highs as focus pivots to earnings
- Oil prices fall nearly 2% as Middle East supply concerns ease
- U.S. 10-year yield climb revives dotcom-era parallels: UBS weighs in
- Goldman flags 2 key market risks if a climb in yields persists
- Shell CEO says Middle East oil flows reach 80% of prewar levels
Tweet
Share
E-mailGet Alerts BMTI Hot Sheet
Price: $9.49 --0%
Financial Fact:
Research and development: 1.93M
Today's EPS Names:
MAYS, APLD, LEVI, More
Financial Fact:
Research and development: 1.93M
Today's EPS Names:
MAYS, APLD, LEVI, More
Join SI Premium – FREE
BioMimetic Therapeutics, Inc. (Nasdaq: BMTI) reported Q1 EPS of ($0.22), versus ($0.28) reported last year. Revenue for the quarter came in at $466.38 million, versus $398.7 million reported last year.
For earnings history and earnings-related data on BioMimetic Therapeutics, Inc. (BMTI) click here.
For earnings history and earnings-related data on BioMimetic Therapeutics, Inc. (BMTI) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Constellation Brands (STZ) Beats Q2 EPS by 13c, Revenue Beats, Offers Guidance
- AXIL Brands (AXIL) Reports Q1 EPS of $0.05
- Penguin Solutions (PENG) Tops Q4 EPS by 23c, Offers Guidance
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
